BioCryst Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	599.82	450.71	331.41	270.83	157.17	17.81
Revenue Growth (YoY)	45.38%	36.00%	22.37%	72.31%	782.38%	-63.53%
Cost of Revenue	189.36	185.92	216.65	259.89	216.07	124.64
Gross Profit	410.45	264.79	114.76	10.94	-58.9	-106.83
Selling, General & Admin	333.09	266.07	213.54	159.37	118.82	62.9
Operating Expenses	333.09	266.07	213.54	159.37	118.82	62.9
Operating Income	77.36	-1.28	-98.78	-148.44	-177.72	-169.73
Interest Expense	-89.19	-98.52	-108.24	-99.09	-59.29	-14.5
Interest & Investment Income	11.35	14.75	15.78	5.13	0.06	0.53
Currency Exchange Gain (Loss)	-0.63	-0.64	-1.04	-1.98	-0.7	-0.97
EBT Excluding Unusual Items	1.56	-85.69	-192.28	-244.38	-237.65	-184.67
Merger & Restructuring Charges	-1.26	-1.26	-3.38	-	-	-
Gain (Loss) on Sale of Investments	-	-	-	-	0	-
Asset Writedown	-	-	-1.55	-	-	-
Legal Settlements	-	-	-	-	-	3.87
Other Unusual Items	-6.91	-	-29.02	-	55.84	-2.01
Pretax Income	-6.62	-86.95	-226.23	-244.38	-181.81	-182.81
Income Tax Expense	2.16	1.93	0.31	2.73	2.25	-
Net Income	-8.78	-88.88	-226.54	-247.12	-184.06	-182.81
Net Income to Common	-8.78	-88.88	-226.54	-247.12	-184.06	-182.81
Shares Outstanding (Basic)	209	207	192	186	179	167
Shares Outstanding (Diluted)	209	207	192	186	179	167
Shares Change (YoY)	1.84%	7.54%	3.38%	3.79%	7.08%	44.70%
EPS (Basic)	-0.04	-0.43	-1.18	-1.33	-1.03	-1.09
EPS (Diluted)	-0.05	-0.43	-1.18	-1.33	-1.03	-1.09
Free Cash Flow	47.86	-53.14	-97.31	-163.2	-144.54	-135.62
Free Cash Flow Per Share	0.23	-0.26	-0.51	-0.88	-0.81	-0.81
Gross Margin	68.43%	58.75%	34.63%	4.04%	-37.48%	-
Operating Margin	12.90%	-0.28%	-29.81%	-54.81%	-113.07%	-952.90%
Profit Margin	-1.46%	-19.72%	-68.36%	-91.25%	-117.11%	-1026.35%
Free Cash Flow Margin	7.98%	-11.79%	-29.36%	-60.26%	-91.97%	-761.41%
EBITDA	80.43	1.73	-95.91	-146.18	-176.83	-168.98
EBITDA Margin	13.41%	0.39%	-28.94%	-53.98%	-112.51%	-
D&A For EBITDA	3.07	3.01	2.87	2.25	0.89	0.75
EBIT	77.36	-1.28	-98.78	-148.44	-177.72	-169.73
EBIT Margin	12.90%	-0.28%	-29.81%	-54.81%	-113.07%	-
Revenue as Reported	-	-	-	-	-	17.81
Advertising Expenses	-	13.57	14.4	14.89	5.71	6.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.